CIM Commercial

Seritage Growth Properties

Ashford Hospitality

Strawberry Fields REIT LLC

CoreCivic

Generation Income Properties

Franklin Street Properties

Wheeler REIT

Arbor Realty Trust

Community Healthcare

United States

NEW YORK--(BUSINESS WIRE)--Rithm Capital Corp. (NYSE: RITM) (“Rithm”), a global alternative asset manager, today announced the closing of a joint venture with a fund managed by DRA Advisors LLC (“DRA”) for the ownership of 1301 Avenue of the Americas, one of the flagship assets in the New York City office portfolio of Elecor Properties (“Elecor”), Rithm's real estate operating platform. Rithm, through Elecor, will continue to hold majority ownership of the asset and operate the building on beha.

Rithm Capital and DRA Advisors Announce Joint Venture for Ownership of 1301 Avenue of the Americas

NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to 10 classes of mortgage-backed notes from New Residential Mortgage Loan Trust 2026-NQM10 (NRMLT 2026-NQM10), a $494.0 million non-prime RMBS transaction sponsored by Rithm Capital Corp. (formerly New Residential Investment Corp.), a publicly traded (NYSE: RITM) real estate investment trust (REIT). The underlying mortgages in the subject pool were primarily originated by NewRez LLC (56.6%). In addition, all loans will be serviced by S.

KBRA Assigns Preliminary Ratings to New Residential Mortgage Loan Trust 2026-NQM10 (NRMLT 2026-NQM10)

Most dividend growth stocks make you choose between a fat yield today and a raise streak you can actually trust over decades, but two landlords have quietly refused that trade-off for more than a quarter century running.

October's Income Picks: 2 Stocks Yielding Over 4% That Have Raised Payouts for 25 Years

SEATTLE, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that data from the Company's lapemelanotide zapixetar (also known as [²¹²Pb]VMT01) program have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting & Pre-Conference Programs taking place November 4 to 8, 2026, in Phoenix, Arizona. SITC plans to release further details for regular abstracts on November 3, 2026.

Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026

Rent, utilities, insurance premiums and grocery bills arrive every month. Most dividend stocks pay four times a year, which forces an income investor to stretch each quarterly check across three months of expenses.

Want $350 a Month in Passive Income? Invest $20,000 Into These 3 Monthly Dividend Stocks

Independence Realty Trust, Inc. (NYSE: IRT - Get Free Report) hit a new 52-week low during trading on Wednesday. The stock traded as low as $14.45 and last traded at $14.5020, with a volume of 373399 shares. The stock had previously closed at $14.83. Analysts Set New Price Targets Several equities research analysts have recently weighed

Independence Realty Trust (NYSE:IRT) Sets New 1-Year Low – Time to Sell?

NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced two poster presentations at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting. The presentations address two distinct areas of cancer research: tumor-cell killing in checkpoint inhibitor–resistant colorectal cancer liver metastases and elimination of senescent tumor cells and fibroblasts.

MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026

- Atebimetinib enhances PD-1 checkpoint blockade in preclinical models of RAS mutant tumors - - Findings provide additional mechanistic rationale for upcoming Phase 2 study of atebimetinib in combination with PD-1 blockade in lung cancer patients - NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that a poster will be presented at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 4-8, 2026, in Phoenix, AZ, demonstrating that atebimetinib enhances PD-1 checkpoint blockade in RAS mutant tumor models. These findings support Immuneering's plans to conduct a Phase 2 study of atebimetinib in combination with PD-1 blockade in patients with lung cancer.

Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

[url="]Agenus Inc.[/url] (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), a

Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026

Simon Property Group, Inc. (NYSE: SPG - Get Free Report) Director Randall Lewis acquired 65 shares of the firm's stock in a transaction on Wednesday, September 30th. The shares were bought at an average cost of $202.78 per share, for a total transaction of $13,180.70. Following the completion of the acquisition, the director owned 7,083 shares

Simon Property Group (NYSE:SPG) Director Randall Lewis Purchases 65 Shares of Stock

Baby boomers are turning 80 in waves while new senior housing construction has nearly stopped, and that collision of demographics and supply is reshaping how much income four REITs can realistically promise their investors.

4 Senior Housing REITs for Income Investors Betting on an Aging America

A guaranteed check for life sounds like an easy win over a dividend portfolio, but the tradeoff involves more than just monthly income, and for some retirees the math flips in a surprising direction.

Which Pays a 66-Year-Old More for Life: A $540,000 Annuity or a $540,000 Dividend Portfolio?

Five dividend stocks go ex-dividend within the next three trading days, but their yields tell only part of the story. The coverage behind those payouts ranges from rock-solid to genuinely alarming, and the clock is already running.

5 High-Yield Dividends That Pay You Soon (But You Must Act Now)

Realty Income has gone from yielding a little more than 5% to more than 6% in recent weeks. It has come through with 136 dividend hikes since its public listing 32 years ago.

10-Year Treasury Notes Yield 5.2% Right Now. Here's Why I'd Still Choose Realty Income for Passive Income.

Panmure Liberum has maintained its 'buy' rating on Land Securities Group PLC (LSE:LAND), the property investment company, with a target price of 710p, after the company agreed to acquire the Metrocentre shopping centre in Gateshead. Landsec has exchanged contracts to buy 100% of Metrocentre for £516 million in net cash consideration, funded through a roughly £500 million equity raise and existing debt facilities.

Panmure Liberum keeps 'buy' rating on Landsec after Metrocentre acquisition

Stocks clawed back from a wild Thursday session, oil surged past $100, and Wall Street analysts reshuffled their bets on names from Airbnb to Northrop Grumman. Find out which stocks got upgraded, downgraded, or newly covered heading into the first Friday of Q4 2026.

Here Are Friday’s Top Wall Street Analyst Research Calls: Abbott Laboratories, Airbnb, Cerebras Systems, Coinbase Global, Edison International, Northrop Grumman, Pershing Square, Robinhood Markets, and More

Chimera Investment Corporation (NYSE: CIM - Get Free Report) gapped down prior to trading on Wednesday. The stock had previously closed at $10.20, but opened at $9.84. Chimera Investment shares last traded at $9.8550, with a volume of 164,202 shares trading hands. Analyst Upgrades and Downgrades Several research analysts have commented on the company. Wall Street

Chimera Investment (NYSE:CIM) Shares Gap Down – Time to Sell?

ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company's Phase 1 clinical data of its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel (zugo-cel) targeting CD19 for autoimmune disease, will be presented at the American College of Rheumatology (ACR) Convergence 2026.

CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced a poster presentation of updated data in patients with immune-checkpoint inhibitor (ICI)-resistant advanced melanoma from the Phase 1 single-center first-in-human (FIH) study and the Phase 1/2 Agni-01 multicenter study of amsoki.

Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting

Simon Property Group, Inc. (NYSE: SPG - Get Free Report) Director Peggy Roe bought 88 shares of the stock in a transaction dated Wednesday, September 30th. The stock was bought at an average price of $202.78 per share, with a total value of $17,844.64. Following the acquisition, the director owned 8,135 shares in the company, valued

Simon Property Group (NYSE:SPG) Director Peggy Roe Acquires 88 Shares of Stock

NEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that the Company will present data from its aglatimagene besadenovec program in non-small cell lung cancer (NSCLC) in patients with progressive NSCLC despite immune checkpoint inhibitor (ICI) treatment, as well as clinical and mechanistic findings from its phase 1b clinical trial of linoserpaturev in recurrent glioblastoma, through two accepted poster presentations at the Society for Immunotherapy of Cancer's (SITC) 41st Annual Meeting, taking place November 4-8, 2026 in Phoenix, Arizona.

Candel Therapeutics to Present at the SITC 2026 Annual Meeting

DALLAS--(BUSINESS WIRE)--NETSTREIT Corp. (NYSE: NTST) (the “Company”) announced the closing of $550.0 million in additional financing commitments and amendments to its existing credit facilities agented by PNC Bank, National Association (the “PNC Credit Agreement”), Wells Fargo Bank, National Association (the “Wells Fargo Credit Agreement”) and Truist Bank (the “Truist Credit Agreement”).The amendment to the Term Loan Agreement, agented by PNC Bank, National Association (as amended, the “PNC Ter.

NETSTREIT Corp. Announces $550.0 Million in Additional Financing Commitments and Amendments to Existing Credit Facilities

XRP is the only major cryptocurrency down this week, and on-chain data from Binance may explain why. But the real reason traders are watching closely has less to do with supply and more to do with what happens when Evernorth goes public on October 8.

XRP Supply on Binance Is the Highest Since January 2025. Is That Why XRP Is Stuck at $1.50?

Obsidian Therapeutics, Inc. (âObsidianâ) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop

Oral presentation highlighting updated clinical data from at least 20 patients with refractory rheumatoid arthritis (RA), 11 patients with Sjögren disease (SjD) and at least five patients with systemic sclerosis (SSc) treated with AlloNK plus rituximab in the ongoing Phase 2a basket trial, all with at least six months of follow-up Poster presentation highlighting deep, consistent B-cell depletion comparable to that observed with CD19 CAR T-cell therapies and a favorable tolerability profile across immune-mediated diseases Poster presentation characterizing the high unmet medical need and low clinical response rates among patients with refractory RA following an inadequate response to at least two distinct classes of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), a population similar to that being studied in the Phase 3 registrational trial Live webcast on Monday, November 9, 2026 at 8:15 am EST to review Artiva's presentations, including an in-depth analysis of data from at least 10 patients with refractory RA who have at least six months of follow-up and would meet key eligibility criteria for the Phase 3 registrational trial SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced one oral and two poster presentations at ACR Convergence 2026 featuring updated data from its AlloNK® program and a registry analysis of the high unmet medical need in refractory RA. Artiva will host a live webcast on Monday, November 9, 2026, at 8:15 am EST to review its ACR presentations and updated clinical data from at least 20 patients with refractory RA who have at least six months of follow-up.

Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026

EPR Properties

Agree Realty

Alexandria

STAG Industrial

American Tower

W. P. Carey

Essential Properties

Crown Castle

Realty Income

Prologis

Outstanding dividend history and a safe payout ratio

Best Dividend REITs

Top Scorers

The 10 most popular REITs by page views on alreits

Dividend Streak 20y

REITs that have been growing dividends for more than 10 years

Dividend Growth Streak 10y

Equity REITs that have been reporting bad results over the last few years and therefore are considered riskier for a beginner investor

Equity REITs to Avoid

REITs that have been reporting good results and are easier to understand for a beginner investor

REITs For Beginners

All Equity REITs

Top Equity REITs with 5-Year Earnings per Share Growth, Ranked by Discount to 52-Week High

Discount to 52-week High

REITs with the lowest Debt/Assets ratio and a positive 5-year CAGR Earnings per Share growth

Low Leverage

REITs that offer a higher starting yield without compromising growth and dividend safety - the sweet spot for income-focused investors

Sweet Spot

BSR REIT

True North Commercial REIT

Automotive Properties

Morguard REIT

CT REIT

Allied Properties

H&R REIT

Inovalis REIT

Nexus Industrial REIT

Chartwell Retirement Residences

Canada

Slate Grocery REIT, a Canadian-listed company that owns grocery-anchored retail centres in the United States, capped a volatile bout of trading with news of its acquisition by two American buyers.
On Monday, Slate announced its sale to Brixmor Property Group …

American buyers acquire Slate Grocery REIT days after announcement of distribution cut

Slate Grocery REIT SGR-UN-T has signed a deal to be acquired by Brixmor Property Group Inc. BRX-N and Everview Partners in an agreement that values the trust at US$2.3-billion.
The purchase comes after Slate launched a review of strategic alternatives in May.…

Slate Grocery REIT to be acquired by Brixmor, Everview Partners in deal valued at $2.3-billion

Slate Grocery REIT Enters into Definitive Agreement to be Acquired by Brixmor and Everview Partners in a US$2.3 Billion Transaction for US$13.00 per Unit in Cash
Transaction Highlights
- All-cash transaction of US$13.00 per Unit, representing a total enterpri…

Slate Grocery REIT Enters into Definitive Agreement to be Acquired by Brixmor and Everview Partners in a US$2.3 Billion Transaction for US$13.00 per Unit in Cash

Brixmor Property Group (BRX) and Everview Partners said Monday they have signed definitive agreement

SMARTER REIT INVESTING STARTS HERE

United States

Performance Heatmap

Sectors

Gainers Today

Losers Today

Popular REITs

News

Explore

Canada

Performance Heatmap

@-webkit-keyframes mui-auto-fill{from{display:block;}}@keyframes mui-auto-fill{from{display:block;}}@-webkit-keyframes mui-auto-fill-cancel{from{display:block;}}@keyframes mui-auto-fill-cancel{from{display:block;}}Sectors

Sectors

Gainers Today

Losers Today

Popular REITs

News

Explore

Singapore

Performance Heatmap

@-webkit-keyframes mui-auto-fill{from{display:block;}}@keyframes mui-auto-fill{from{display:block;}}@-webkit-keyframes mui-auto-fill-cancel{from{display:block;}}@keyframes mui-auto-fill-cancel{from{display:block;}}Sectors

Sectors

Gainers Today

Losers Today

Popular REITs

News

Explore

United Kingdom

Performance Heatmap

@-webkit-keyframes mui-auto-fill{from{display:block;}}@keyframes mui-auto-fill{from{display:block;}}@-webkit-keyframes mui-auto-fill-cancel{from{display:block;}}@keyframes mui-auto-fill-cancel{from{display:block;}}Sectors

Sectors

Gainers Today

Losers Today

Popular REITs

News

Explore

France

Performance Heatmap

@-webkit-keyframes mui-auto-fill{from{display:block;}}@keyframes mui-auto-fill{from{display:block;}}@-webkit-keyframes mui-auto-fill-cancel{from{display:block;}}@keyframes mui-auto-fill-cancel{from{display:block;}}Sectors

Sectors

Gainers Today

Losers Today

Popular REITs

News

Explore

India

Performance Heatmap

@-webkit-keyframes mui-auto-fill{from{display:block;}}@keyframes mui-auto-fill{from{display:block;}}@-webkit-keyframes mui-auto-fill-cancel{from{display:block;}}@keyframes mui-auto-fill-cancel{from{display:block;}}Sectors

Sectors

Gainers Today

Losers Today

Popular REITs

News

Explore

South Africa

Performance Heatmap

@-webkit-keyframes mui-auto-fill{from{display:block;}}@keyframes mui-auto-fill{from{display:block;}}@-webkit-keyframes mui-auto-fill-cancel{from{display:block;}}@keyframes mui-auto-fill-cancel{from{display:block;}}Sectors

Sectors

Gainers Today

Losers Today

Popular REITs

News

Explore

When selecting REITs for investment, remember that it is the strong ones that can attract additional capital - and this provides the greatest long-term potential.

SMARTER REIT INVESTING
STARTS HERE

Sectors

Sectors

Sectors

Sectors

Sectors

Sectors